CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Xiros North America

Xiros turn bright ideas into brilliant implants. We are on a mission to improve patient outcomes by creating innovative implantable textiles and devices.

Nipro Diabetes Systems

TotalDrugmart.com

TotalDrugmart.com is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vallon Pharmaceuticals

Vallon is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. $VLON

Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.